Coherus Looks To Galvanize Pegfilgrastim Biosimilar With New Formats
California-Based Firm Updates On Planned Novel Autoinjector Presentation
Coherus BioSciences spoke at length about its two marketed biosimilars, referencing Neulasta and Lucentis, during the company’s first-quarter earnings call.
